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ABSTRACT 
Idiopathic pulmonary fibrosis (IPF) is a chronic oxido-inflammatory disorder of the lung. Oxidative stress is 
widely recognized as a central feature of IPF. Antioxidant therapy has been proposed as an effective treatment 
for IPF. An array of clinical trials describing the therapeutic impact of these drugs have been reporting albeit 
with conflicting evidence points. We performed a meta-analysis of trials in which efficacy of antioxidant thera-
py was compared with control in IPF. Systematic literature search was conducted in PubMed, EMBASE, the 
Cochrane Library, CPCI-S (Conference Proceedings Citation Index-Science), ICTRP (International Clinical 
Trials Registry Platform), and Google Scholar till June 2016 by two independent researchers. Various outcomes 
such as changes in pulmonary function tests (change in vital capacity [ΔVC], change in forced vital capacity 
[ΔFVC], change in percentage of predicted vital capacity [Δ%VC], and change in percentage of predicted 
carbon monoxide diffusing capacity [Δ%DLco]), changes in 6 minutes walking test distance (Δ6MWT), rates of 
adverse events, and rates of death, were included. All statistical analyses were performed using RevMan V.5.3. 
Twelve studies (n = 1062) were identified that used antioxidants (N-acetylcysteine and lecithinized superoxide 
dismutase) as a treatment for IPF. Overall, there was no association of antioxidant therapy with ΔFVC (SMD = 
0.27, 95% CI:-0.07 to 0.61; P = 0.12), ΔFVC (%) (SMD = -0.10, 95% CI:-0.56 to 0.36; P = 0.66) and 6MWT 
(SMD = -0.04, 95% CI:-0.11 to 0.20; P = 0.59) in IPF patients. However, combined antioxidant therapy was 
found to be associated with %VC (SMD = 0.37, 95% CI: 0.09 to 0.64; P = 0.008) and Δ%DLco (SMD = 0.15, 
95% CI: 0.00 to 0.29; P = 0.05) in IPF patients. Strong evidence was obtained that the antioxidants increased 
adverse effects adverse events (OR = 1.56, 95% CI: 0.75 to 3.24; P = 0.23) but it did not associate mortality (OR 
= 0.96, 95% CI: 0.44 to 2.11; P = 0.92). The use of significant clinical heterogeneity, low statistical power, high 
dropout rates, duration of follow-ups, and dosing regimens of antioxidant agents. Combined antioxidant therapy 
seems to be a safe and effective therapy for IPF patients which provides a more beneficial effect in terms of VC, 
and DLco rather than monotherapy. Further randomized controlled trials with homogeneous outcome measures 
are needed. 
 
Keywords: antioxidant, meta-analysis, idiopathic pulmonary fibrosis, vital capacity, carbon monoxide diffusing 
capacity 
 
 
 
INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a 
chronic progressive, debilitating interstitial 
lung disease with unknown etiology. Dif-
fused scarring (fibrosis) and mild inflamma-
tion are characteristic features of IPC culmi-
nating to a gradual worsening of lung capaci-
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ty (Raghu et al., 2011). In the United States, 
its prevalence ranges between 14 and 27.9 
cases per 100,000 population using narrow 
case definitions, and 42.7 and 63 per 100,000 
population using broad case definitions. In 
Europe, it ranges from 1.25 to 23.4 cases per 
100,000 population (Raghu et al., 2015, 
2016), whereas 494.5 per 100,000 individ-
uals was the prevalence among the Medi-
care-eligible population in 2011 (Raghu et 
al., 2014). In the USA the annual incidence 
rate was estimated at 6.8-8.8 per 100,000 
population using narrow case definitions and 
16.3-17.4 per 100,000 population using 
broad case definitions whereas in Europe it 
ranged between 0.22 and 7.4 per 100,000 
population (Nalysnyk et al., 2012). Mainly 
males over 60 years of age are more affected 
by IPF than females with peak prevalence in 
the eighth decade (du Bois, 2012; Gribbin et 
al., 2006).  
The clinical manifestations of IPF in-
clude shortness of breath and a cough with 
significant impairment in health-related qual-
ity of life (HRQoL). Cigarette smoking, gas-
troesophageal disease, environmental expo-
sure, and possibly infective agents such as 
influenza, Epstein–Barr virus and hepatitis 
are some of the factors that are associated 
with the IPF (American Thoracic Society, 
2000). HRQoL of IPF patients deteriorates 
rapidly with an approximate survival rate of 
2 to 5 years. According to THIN’s database 
cohort, 180 per 1000 person-years (95% CI 
164 to 198 per 1000 person-years) was the 
mortality rate for people with IPF (Gribbin et 
al., 2006). There are only a few effective 
therapies available, and none offers a cure. 
Moreover, the mortality rate is high warrant-
ing the need of new treatments for IPF 
(Bando et al., 2010; Behr et al., 2016; 
Homma et al., 2012; Martinez et al., 2014; 
Tomioka et al., 2005). 
An array of treatments such as anti-
inflammatory therapy with corticosteroids or 
immunosuppressants have been evaluated for 
use in patients. However, this therapy fails to 
significantly improve the survival time of 
patients with IPF (Lee et al., 2011; Pinheiro 
et al., 2008; Taskar and Coultas, 2006; 
Xaubet et al., 2003). Other pharmaco-
therapies such as nintedanib, etanercept, war-
farin, Gleevec, and bosentan have limitations 
owing to their adverse effects (Luppi et al., 
2012). Various working groups which for-
mulate treatment algorithms have found in-
sufficient evidence to recommend any of 
them as full fledged clinical practice guide-
lines (Raghu et al., 2011). In 2011, 
Pirfenidone was approved by the European 
Medicines Agency for the treatment of IPF 
(Jiang et al., 2012; Taniguchi et al., 2010). 
However, a fraction of patients discontinued 
the treatment pertaining to side effects 
(Cottin and Maher, 2015). 
Lungs are the primary organs frequently 
exposed to higher oxygen tension. Several 
clinical and experimental studies have doc-
umented that oxidative stress caused cell 
membrane destruction via generation of free 
radical peroxidation products leading to 
pulmonary fibrosis (Beeh et al., 2002; Cantin 
et al., 1989). Furthermore, a considerable 
body of evidence suggests that antioxidant 
supplementation could be a potentially use-
ful treatment for IPF. Various clinical studies 
have reported the efficacy of antioxidant 
treatment (such as N-acetylcysteine (NAC) 
and lecithinized superoxide dismutase (PC-
SOD)) for IPF (Bando et al., 2010; Behr et 
al., 2009, 2016; Homma et al., 2012; Huang 
et al., 2015; Kamio et al., 2014; Martinez et 
al., 2014; Okuda et al., 2016; Raghu et al., 
2012; Sakamoto et al., 2013, 2015; Tomioka 
et al., 2005). Several studies found that NAC 
treatment had a beneficial effect on lung 
function in IPF patients and significantly 
delayed disease progression (Behr et al., 
2009; Homma et al., 2012; Huang et al., 
2015; Okuda et al., 2016; Sakamoto et al., 
2013, 2015) whereas few studies reported 
that NAC treatment had no benefit and did 
not significantly improve the lung function 
of patients with IPF (Bando et al., 2010; 
Behr et al., 2016; Martinez et al., 2014; 
Raghu et al., 2012). A study by Tomioka et 
al. (Tomioka et al., 2005) showed that N-
acetylcysteine aerosol treatment might delay 
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disease progression, but did not improve 
pulmonary function or quality of life (QoL). 
However, PC-SOD treatment had a benefi-
cial effect on serum markers in IPF patients 
with severe respiratory dysfunction (Kamio 
et al., 2014). As low statistical power may 
limit the interpretability of the findings, the 
results of all of these trials (Bando et al., 
2010; Behr et al., 2009, 2016; Homma et al., 
2012; Huang et al., 2015; Kamio et al., 2014; 
Martinez et al., 2014; Okuda et al., 2016; 
Raghu et al., 2012; Sakamoto et al., 2013, 
2015; Tomioka et al., 2005) should be 
interpreted with caution. In view of this con-
flicting evidence landscape, it is important to 
create an empirical evidence framework to 
underline the degree of therapeutic benefit of 
antioxidant therapy in IPF patients. Hence, 
the aim of the present study was to conduct 
systematic review and meta-analysis of ef-
fectiveness and potential side effects of anti-
oxidants for the treatment of IPF to develop 
a robust evidence base for robust recommen-
dations for clinical decisions. 
 
METHODS 
Data sources and selection criteria 
This systematic review and meta-analysis 
were conducted as per Preferred Reporting 
Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Stewart et 
al., 2015). The following electronic data-
bases were searched: PubMed, EMBASE, 
the Cochrane Library, CPCI-S (Conference 
Proceedings Citation Index-Science), ICTRP 
(International Clinical Trials Registry Plat-
form), and Google Scholar were searched in 
June 2016. Two independent reviewers 
(ADK and AAM) conducted an abstract re-
view of all records. The following keywords 
were used in the search strategy: Diverse an-
ti-oxidative substances, such as vitamin C, 
vitamin E, allopurinol, b-carotene, selenium, 
and methionine, acetylcysteine, N-
acetylcysteine, NAC, idiopathic pulmonary 
fibrosis, and IPF.  
Inclusion criteria were as follows: studies 
that compared an N-acetylcysteine-treated 
group with a control group for the treatment 
of IPF; studies that reported outcome 
measures, including changes in pulmonary 
function tests (change in vital capacity 
[ΔVC], change in forced vital capacity 
[ΔFVC], change in percentage of predicted 
vital capacity [Δ%VC], and change in 
percentage of predicted carbon monoxide 
diffusing capacity [Δ%DLco]), changes in 6 
minutes walking test distance (Δ6MWT), 
rates of adverse events, and rates of death; 
and filtered by articles published in English 
and Humans. 
Exclusion criteria were: experimental 
studies; mechanistic (association) studies; 
Letters/reviews/editorials, commentary, ani-
mal studies, in-vitro studies, Case series 
(sample size <10 patients), case reports, 
pharmacodynamic/pharmacokinetic studies 
and studies with full-text published in a 
language other than English. 
 
Quality assessment of the articles 
The quality of each study included in the 
analysis was assessed using the Cochrane 
Risk of Bias Tool for systematic reviews of 
interventions (version 5.0.1) (Cochrane, 
2008) and also using the Downs and Black 
critical appraisal tool. This validated 
Cochrane Risk of Bias tool consisted of the 
following six categories: (1) random se-
quence generation; (2) allocation conceal-
ment; (3) blinding of participants; (4) in-
complete outcome data; (5) selective out-
come reporting; and (6) other bias. Each cat-
egory was scored as high, uncertain, or low 
ROB. Two independent reviewers performed 
the quality assessment and disagreements on 
scores were resolved through discussion. 
 
Data analysis 
The standard mean difference (SMD) 
was used with 95% confidence intervals (CI) 
and standard deviation (SD). A meta-
analysis was conducted with simultaneous 
use of random-effect models. All statistical 
analyses were performed using RevMan 
V.5.3 (Cochrane, Oxford, UK) software. The 
meta-analysis included data from parallel-
group design studies. Since the data used for 
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the meta-analysis were continuous variables 
such as ΔVC, ΔFVC, Δ%VC, Δ%DLco and 
Δ6MWT, the standardized mean difference 
(SMD) and 95% CI were used for meta-
analysis. Statistical analysis for dichoto-
mized outcomes (rates of adverse events, and 
rates of death) was performed using odds ra-
tio (OR) and 95% CI. Heterogeneity of the 
included studies was tested with the Higgins 
I2 test, and meaningful heterogeneity was 
determined by 50 % of the I2 value. When 
the I2 value was >50, a random-effect model 
was used for the meta-analysis.  
 
RESULTS 
Summary of included studies 
As shown in Figure 1 (PRISMA flow 
chart), the database searches initially yielded 
115 results. After screening, 86 of these 
(study design (16), not relevant dis-
ease/indication (8), review/editorial (12), 
cost study (18), patient population (8) and 
animal/in vitro study (24)) were excluded. 
Further, seventeen more studies were 
deemed irrelevant, based on the title or ab-
stract, and were also excluded. Of the 
remaining twelve studies (Bando et al., 2010; 
Behr et al., 2009, 2016; Homma et al., 2012; 
Huang et al., 2015; Kamio et al., 2014; 
Martinez et al., 2014; Okuda et al., 2016; 
Raghu et al., 2012; Sakamoto et al., 2013, 
2015; Tomioka et al., 2005) were included 
for qualitative and quantitative analysis. 
The primary findings from the included 
studies are summarized in Table 1. Eight 
studies were conducted in Japan (Bando et 
al., 2010; Homma et al., 2012; Huang et al., 
2015; Kamio et al., 2014; Okuda et al., 2016; 
Sakamoto et al., 2013, 2015; Tomioka et al., 
2005), three in multi-countries (Behr et al., 
2009, 2016; Raghu et al., 2012) and one in 
United States (Martinez et al., 2014). Only 
two types of antioxidants (N-Acetylcysteine 
(NAC) (Bando et al., 2010; Behr et al., 2009, 
2016; Homma et al., 2012; Huang et al., 
2015; Martinez et al., 2014; Okuda et al., 
2016; Raghu et al., 2012; Sakamoto et al., 
2013, 2015; Tomioka et al., 2005) and 
lecithinized superoxide dismutase (PC-SOD) 
(Kamio et al., 2014) were reported in these 
studies. Six studies (Bando et al., 2010; 
Homma et al., 2012, Okuda et al., 2016; 
Sakamoto et al., 2013, 2015; Tomioka et al., 
2005) had inhalation as a route of admin-
istration of NAC whereas five studies 
 
Figure 1: PRISMA flow diagram depicting the selection of studies for systematic review and meta-
analysis 
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Table 1: Characteristics of included studies 
Sr. 
No. 
Author; year; 
Country 
Design Intervention and Sample size  
(analyzed) 
Duration of 
study 
Outcomes 
measures 
Adverse 
event  
report 
Author's conclusions 
Antioxidant group Placebo group 
1. Bando et al. 
(2010); Japan 
Retrospective, Open 
case-control trial 
NAC (352.4 mg), Inhala-
tion, 2 times daily  
(n = 14) 
No therapy 
(n = 11) 
48 weeks Δ FVC (L), Δ 
FVC (%) and 
Δ %DLco 
Yes Some mild cases were stable even with-
out NAC treatment, while other cases 
worsened soon despite NAC inhalation 
monotherapy. 
2. Behr et al. (2009); 
Multi-countries 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial, Par-
allel-group trial 
NAC (600 mg), Oral,  
3 times daily (n = 80) 
Placebo, 
matched, oral,  
3 times daily  
(n = 75) 
48 weeks Δ VC (%) and 
Δ %DLco 
No There was favorable effects of NAC on 
lung function in IPF and emphasizes the 
usefulness of VC, DLco, and the CPI for 
the evaluation of a therapeutic effect. 
3. Behr et al. (2016); 
Multi-countries 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial 
Combination therapy: 
PFD (1602 mg/day) and 
NAC (600 mg), Oral,  
3 times daily (n = 61) 
Placebo, 
matched, oral,  
3 times daily  
(n = 62) 
24 weeks Δ FVC (L), Δ 
FVC (%), Δ 
%DLco and Δ 
6MWT 
Yes Addition of NAC to PFD does not substan-
tially alter the tolerability profile of PFD, 
and is unlikely to be beneficial in IPF. 
4. Homma et al. 
(2012); Japan 
Prospective,  
Randomized con-
trolled trial 
NAC (352.4 mg), Inhala-
tion, 2 times daily 
(n = 44) 
No therapy  
(n = 46) 
48 weeks Δ VC (%) and 
Δ FVC (L) 
Yes NAC monotherapy may have some bene-
ficial effect in patients with early stage 
IPF. 
5. Huang et al. 
(2015); Japan 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial 
PFD (1800 mg) and 
NAC (1800 mg), Oral,  
(n = 38) 
NAC (1800 mg 
per day), Oral, 
(n = 38) 
48 weeks Δ FVC (L), Δ 
FVC (%), Δ 
%DLco and Δ 
6MWT 
Yes PFD plus high-dose NAC as compared 
with placebo plus high-dose NAC im-
proved the prolonged PFS.  
6. Kamio et al. 
(2014); Japan 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial 
PC-SOD (40 mg or  
80 mg), Intravenously, 
(n = 17) 
No therapy  
(n = 16) 
8 weeks FVC (%) Yes Treatment with PC-SOD is safe and im-
proves the levels of serum markers such 
as lactate dehydrogenase and surfactant 
protein-A in patients with severe respirato-
ry dysfunction. 
 
7. Martinez et al. 
(2014); United 
State 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial 
NAC (600 mg), Oral,  
3 times daily  
(n = 133) 
Placebo,  
3 times daily 
(n = 131) 
60 weeks Δ FVC (L), Δ 
%DLco and Δ 
6MWT 
Yes As compared with placebo, NAC offered 
no significant benefit with respect to the 
preservation of FVC in patients with IPF 
with mild to moderate impairment in lung 
function. 
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Sr. 
No. 
Author; year; 
Country 
Design Intervention and Sample size  
(analyzed) 
Duration of 
study 
Outcomes 
measures 
Adverse 
event  
report 
Author's conclusions 
Antioxidant group Placebo group 
8. Okuda et al. 
(2016); Japan 
Single-arm,  
Prospective clinical 
trial 
NAC (352.4 mg),  
Inhalation, 2 times daily  
(n = 28) 
No therapy  
(n = 46) 
48 weeks Δ FVC (L) Yes Inhaled NAC therapy was effective in pa-
tients with mild-to moderate IPF and was 
more beneficial in patients who had 
greater declines in FVC before the initia-
tion of therapy. 
9. Raghu et al. 
(2012); Multi-
countries 
Double-blind,  
Placebo-controlled 
trial, Randomized 
controlled trial 
Combination therapy: 
AZA (150 mg/day), PDN 
(0.5 mg/kg) and NAC 
(600 mg, 3 times/day), 
Oral, (n = 77) 
No therapy  
(n = 78) 
60 weeks Δ FVC (L), Δ 
%DLco, Δ 
6MWT 
 
Yes Increased risks of death and hospitaliza-
tion were observed in patients with idio-
pathic pulmonary fibrosis who were 
treated with a combination of PDN, AZA, 
and NAC, as compared with placebo. 
10. Sakamoto et al. 
(2013); Japan 
Retrospective study Combination therapy: 
PFD therapy (1,200-
1,800 mg/day), oral and 
NAC (352.4 mg), Inhala-
tion, 2 times daily  
(n = 11) 
No therapy  
(n = 7) 
48 weeks Δ FVC (L) No Patients treated with PFD combined with 
NAC therapy exhibited favorable out-
comes. 
11. Sakamoto et al. 
(2015); Japan 
Case-control  Combination therapy: 
PFD (1,200-1,800 
mg/day), oral and NAC 
(352.4 mg), Inhalation,  
2 times daily (n = 17) 
 
PFD (1,200-
1,800 mg/day), 
oral (n = 10) 
48 weeks Δ FVC (L) Yes Combined treatment with NAC and PFD 
might improve the poor prognosis of pa-
tients with advanced IPF. 
12. Tomioka et al. 
(2005); Japan 
Open, Randomized 
controlled trial 
NAC (176 mg), inhala-
tion, 2 times daily  
(n = 10) 
BH (2 mg), inha-
lation 2 times 
daily  
(n = 12) 
48 weeks Δ VC (%), Δ 
%DLco, Δ 
6MWT 
Yes Although long-term aerosolized NAC ad-
ministration did not influence pulmonary 
function or QoL, it may delay disease pro-
gression as evidenced by exercise desat-
uration, high-resolution CT, and serum 
KL-6. 
NAC: N-acetylcysteine; PFD: Pirfenidone; AZA: Azathioprine; PDN: Prednisone; PFS: Progression-Free Survival; PC-SOD: lecithinized superoxide dismutase; BH: Bromhexine hydrochloride 
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(Behr et al., 2009, 2016; Huang et al., 2015; 
Martinez et al., 2014; Raghu et al., 2012) in-
dicated NAC as an oral treatment and in only 
one study (Kamio et al., 2014) PC-SOD was 
administered intravenously. 
 
Characteristics of the studies included 
Table 1 shows the study characteristics. 
There was a total of 1,062 enrolled patients, 
of which 530 (49.9 %) patients received an-
tioxidant treatment, whereas remaining were 
on placebo. Eight studies were randomized 
controlled trials (seven were double blinded 
(Behr et al., 2009, 2016; Homma et al., 
2012; Huang et al., 2015; Kamio et al., 2014; 
Martinez et al., 2014; Raghu et al., 2012) and 
one was open arm (Tomioka et al., 2005)); 
while three were retrospective studies 
(Bando et al., 2010; Sakamoto et al., 2013), 
one had a single-arm prospective clinical 
trial (Okuda et al., 2016) and case-control 
trial study (Sakamoto et al., 2015), 
respectively. 
Health status of IPF patients was 
determined by ΔFVC, Δ%VC, Δ%DLco, and 
Δ6MWT. The change in percentage of 
predicted vital capacity [Δ%VC] was 
measured in three studies (Behr et al., 2009; 
Homma et al., 2012; Tomioka et al., 2005), 
change in forced vital capacity [ΔFVC] was 
measured in eleven studies (Bando et al., 
2010; Behr et al., 2016; Homma et al., 2012; 
Huang et al., 2015; Kamio et al., 2014; 
Martinez et al., 2014; Okuda et al., 2016; 
Raghu et al., 2012; Sakamoto et al., 2013, 
2015; Tomioka et al., 2005) whereas seven 
studies (Bando et al., 2010; Behr et al., 2009, 
2016; Huang et al., 2015; Martinez et al., 
2014; Raghu et al., 2012; Tomioka et al., 
2005) measured change in percentage of 
predicted carbon monoxide diffusing 
capacity [Δ%DLco] and five studies (Behr et 
al., 2016; Huang et al., 2015; Martinez et al., 
2014; Raghu et al., 2012; Tomioka et al., 
2005) measured changes in 6 minutes 
walking test distance (Δ6MWT). Adverse 
events were reported by ten studies (Bando 
et al., 2010; Behr et al., 2016; Homma et al., 
2012; Huang et al., 2015; Kamio et al., 2014; 
Martinez et al., 2014; Okuda et al., 2016; 
Raghu et al., 2012; Sakamoto et al., 2015; 
Tomioka et al., 2005). 
 
Risk of bias 
The ROB assessment for the included 
studies is presented in Figure 2. Of the 12 
studies identified for analysis in this study, 
six were classified as high quality (Behr et 
al., 2009, 2016; Huang et al., 2015; Kamio et 
al., 2014; Martinez et al., 2014; Raghu et al., 
2012)and six as low quality (Bando et al., 
2010; Homma et al., 2012; Okuda et al., 
2016; Sakamoto et al., 2013, 2015; Tomioka 
et al., 2005). However, adverse effects as-
sessing of funnel plots for subgroup analysis 
revealed an asymmetric distribution, sug-
gesting publication bias (Figure 3). 
Downs and Black scoring were used to 
evaluate the quality of the studies. Study 
quality was variable. The overall quality of 
study reporting was good, external validity 
was low, internal validity was better amongst 
studies (Table 2). A heat map of an overview 
of the quality of the studies determined using 
Downs and Black scoring system is provided 
in Supplementary material. 
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Figure 2: Risk of bias graph of included trials: Review authors’ judgments about each risk of bias item 
for each included study (A) and review authors’ judgments about each risk of bias item presented as 
percentages across all included studies (B).  
 
 
Table 2: Review of the quality of studies determined using Downs and Black scoring system 
No. Author Reporting
(Max: 11) 
External 
Validity 
(Max: 3) 
Internal 
validity-
bias 
(Max: 7) 
Internal validi-
ty-confounding 
(selection bias) 
(Max: 6) 
Total 
(27) 
1. Bando et al. (2010) 9 3 3 2 17 
2. Behr et al. (2009) 11 3 7 6 27 
3. Behr et al. (2016) 11 3 7 6 27 
4. Homma et al. (2012) 9 3 3 5 20 
5. Huang et al. (2015) 10 3 7 6 26 
6. Kamio et al. (2014) 10 3 7 6 26 
7. Martinez et al. (2014) 10 3 7 6 26 
8. Okuda et al. (2016) 5 3 3 2 13 
9. Raghu et al. (2012) 9 3 3 4 19 
10. Sakamoto et al. (2013) 10 3 3 0 16 
11. Sakamoto et al. (2015) 11 3 7 6 27 
12. Tomioka et al. (2005) 9 3 3 4 19 
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Figure 3: Publication bias analysis by using 
funnel plot  
 
 
Conflicting evidence 
Many antioxidants (including NAC and 
PC-SOD) have recently received increased 
attention as a novel treatment for IPF. A 
number of studies have evaluated the 
efficacy and safety of this antioxidant for the 
treatment of IPF, but with conflicting results 
(Bando et al., 2010; Behr et al., 2009, 2016; 
Homma et al., 2012; Huang et al., 2015; 
Kamio et al., 2014; Martinez et al., 2014; 
Okuda et al., 2016; Raghu et al., 2012; 
Sakamoto et al., 2013, 2015; Tomioka et al., 
2005). Several studies found that NAC 
treatment had a beneficial effect on lung 
function in IPF patients and significantly 
delayed disease progression (Behr et al., 
2009; Homma et al., 2012; Huang et al., 
2015; Okuda et al., 2016; Sakamoto et al., 
2013, 2015) whereas few studies reported 
that NAC treatment had no benefit and did 
not significantly improve the lung function 
of patients with IPF (Bando et al., 2010; 
Behr et al., 2016; Martinez et al., 2014; 
Raghu et al., 2012). A study by Tomioka et 
al. (2005) showed that N-acetylcysteine aer-
osol treatment might delay disease progres-
sion, but did not improve pulmonary func-
tion or QoL. However, PC-SOD treatment 
had a beneficial effect on serum markers in 
IPF patients with severe respiratory dysfunc-
tion (Kamio et al., 2014). As low statistical 
power may limit the interpretability of the 
findings thus results of all of these trials 
(Bando et al., 2010; Behr et al., 2009, 2016; 
Homma et al., 2012; Huang et al., 2015; 
Kamio et al., 2014; Martinez et al., 2014; 
Okuda et al., 2016; Raghu et al., 2012; 
Sakamoto et al., 2013, 2015; Tomioka et al., 
2005) should be interpreted with caution. 
 
Outcomes 
Because of heterogeneity in the studies, 
we used a random-effects model for the 
analysis of ΔFVC (L), ΔFVC (%), Δ%VC, 
Δ%DLco, Δ6MWT, adverse events and 
death (Table 3).  
Effect of antioxidant on Δ%VC 
As shown in Figure 4A, antioxidant 
combination resulted in a significant change 
in %VC, with an overall effect size (Z) of 
2.64 (p = 0.008) and no evidence of hetero-
geneity was observed (I2 = 0 %; P = 0.87). 
The decrease in %VC was significantly less 
in the antioxidant group than in the control 
group (SMD = 0.37, 95% CI: 0.09 to 0.64; P 
= 0.008). 
 
Table 3: Clinical outcomes of antioxidant group compared with control group 
Outcomes Heterogeneity Analysis 
Model 
Summary 
Statistic 
Overall Effect No.  
Trials I2, % P Value SMD/OR (95% CI) P Value 
∆ VC (%) 0 0.87 Random SMD 0.37 (0.09, 0.64) 0.008 3 
∆ FVC (L) 78 0.0001 Random SMD 0.27 (-0.07, 0.61) 0.12 9 
∆ FVC (%) 58 0.07 Random SMD -0.10 (-0.56, 0.36) 0.66 4 
∆ 6MWT 63 0.03 Random SMD 0.04 (-0.11, 0.20) 0.59 5 
∆ %DLco 0 0.56 Random SMD 0.15 (0.00, 0.29) 0.05 7 
Rate of AE 61 0.0008 Fixed OR 1.56 (0.75, 3.24) 0.23 9 
Rate of death 56 0.02 Fixed OR 0.96 (0.44, 2.11) 0.92 11 
EXCLI Journal 2016;15:636-651 – ISSN 1611-2156 
Received: September 01, 2016, accepted: October 15, 2016, published: November 07, 2016 
 
 
645 
 
Figure 4: Forest plot evaluating effects of antioxidants on ∆%VC (A), ∆FVC (L) (B) and ∆FVC (%) (C) 
compared with control group by using random-effects model 
 
 
Effect of antioxidant on ΔFVC 
The efficacy of antioxidant treatment in 
reduction of FVC (L) lost its statistical sig-
nificance (Z = 1.54; P = 0.12). There was 
heterogeneity between the studies (I2 = 
78 %; p = 0.0001). There were no statistical-
ly significant differences in FVC (L) in the 
antioxidant group than in the control group 
(SMD = 0.27, 95% CI:-0.07 to 0.61; P = 
0.12) (Figure 4B). 
The intervention of antioxidant use did 
not associate with a significant decrease in 
ΔFVC (%) (Z = 0.44; P = 0.66), however it 
has acceptable heterogeneity among the stud-
ies (I2 = 58 %; P = 0.07). There were no sta-
tistically significant differences in FVC (%) 
in the antioxidant group than in the control 
group (SMD = -0.10, 95% CI:-0.56 to 0.36; 
P = 0.66) (Figure 4C). 
Effect of antioxidant on 6MWT  
The intervention of antioxidant used, was 
associated with a less significant decline in 
6MWT (Z = 0.53; P = 0.59), with substantial 
heterogeneity among the studies (I2 = 63 %; 
P = 0.03). The decline in 6MWT was signifi-
cantly less in the antioxidant group than in 
the control group (SMD = -0.04, 95% CI:-
0.11 to 0.20; P = 0.59) (Figure 5A). 
Effect of antioxidant on Δ%DLco 
As shown in Figure 5B, antioxidant 
combination resulted in a significant change 
in Δ%DLco, with an overall effect size (Z) 
of 1.99 (p = 0.05) and no evidence of hetero-
geneity was observed (I2 = 0 %; P = 0.56). 
The change in Δ%DLco was significantly 
less in the antioxidant group than in the con-
trol group (SMD = 0.15, 95% CI: 0.00 to 
0.29; P = 0.05). 
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Figure 5: Forest plot evaluating effects of antioxidants on ∆%DLco (A) and ∆6MWT (B) compared 
with control group by using random-effects model 
 
 
Adverse effects of antioxidants 
We also performed meta-analyses re-
garding any adverse effects of antioxidants 
mentioned in the included studies. There 
were also no statistically significant differ-
ences in the occurrence of adverse events 
(OR = 1.56, 95% CI: 0.75 to 3.24; P = 0.23) 
with substantial heterogeneity among the 
studies (I2 = 61 %; P = 0.0008) (Figure 6A). 
Effect of antioxidant on rate of death 
The intervention of antioxidant used, did 
not associate with a significant death (Z = 
0.11; P = 0.92), however it has acceptable 
heterogeneity among the studies (I2 = 56 %; 
P = 0.02). There were no statistically signifi-
cant differences in rate of death in the anti-
oxidant group than in the control group (OR 
= 0.96, 95% CI: 0.44 to 2.11; P = 0.92) (Fig-
ure 6B). 
 
DISCUSSION 
An array of factors that are associated 
with IPF such as prognostic factors, stage of 
IPF, complications, as well as comorbidities 
as these needs to be addressed before treating 
IPF patients. Various non-pharmacological 
treatments such as respiratory rehabilitation, 
home oxygen therapy, cell and gene therapy, 
lung transplantation, and palliative care have 
been reported to produce beneficial effect up 
to some extent in IPF patients (Chan et al., 
2013; Xaubet et al., 2013). However, these 
treatment strategies failed to address the is-
sues such as risk factors that may aggravate 
IPF as well as unable to provide symptomat-
ic relief (Richeldi et al., 2003). Hence, 
pharmacological interventions acquired more 
attention as treatment strategies for IPF 
(Bando et al., 2010; Behr et al., 2009, 2016; 
Chan et al., 2013; Demedts et al., 2005; 
Homma et al., 2012; Jiang et al., 2012; 
Martinez et al., 2014; Taniguchi et al., 2010; 
Tomioka et al., 2005). 
According to American Thoracic Socie-
ty–European Respiratory Society, the rec-
ommended therapy for IPF consists of pred-
nisone and azathioprine (American Thoracic 
Society, 2000). However, there is limited ev-
idence supporting prednisone for cough sup-
pression in IPF. Another agent that might be 
useful as a therapy for treatment of IPF is 
pirfenidone, but its effect as a single agent is 
not well established (Azuma et al., 2005). 
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Figure 6: Forest plot evaluating effects of antioxidants on the rate of adverse events (A) and rate of 
death (B) compared with the control group by using a random-effects model 
 
 
Moreover, these agents also associated 
with an array of side effects such as physical 
deconditioning after administration of pred-
nisone and myelotoxic effects with azathio-
prine. However, there is increasing evidence 
suggesting that oxidant-mediated alveolar 
epithelial cell injury along with abnormal fi-
broblast response is responsible for genera-
tion and maintenance of IPF (Chan et al., 
2013). With this view, administration of 
agents with antioxidant potential might be 
useful for the treatment of IPF. Hence, in this 
systematic review and meta-analysis, we 
evaluated the efficacy of antioxidant in the 
management of patients with IPF.  
Meta-analysis is an important statistical 
tool and essential part of a systematic review 
which aids clinical decision-making. An ar-
ray of studies revealed that antioxidant ther-
apy showed a potent effect against IPF. 
However, the clinical implication remains 
sporadic worldwide. The trial of Kamio et al. 
(2014) showed that treatment with 
antioxidants improve the levels of serum 
markers in patients with severe respiratory 
dysfunction that improved the QoLin IPF 
patients (Kamio et al., 2014) whereas Bando 
et al. (2010) showed that QoL of IPF patients 
worsened with antioxidant therapy (Bando et 
al., 2010). Thus, these conflicts led us to 
investigate the effectiveness of antioxidants 
in IPF further by meta-analyzing the data 
collated from these studies. Previous system-
atic review and meta-analyses of antioxidant 
therapy in the management of IPF were una-
ble to forge a conclusive body of evidence 
due to few RCTs which reported the effect of 
antioxidant treatments on IPF. 
The role of antioxidants in the treatment 
of IPF has been studied by various 
researchers (Bando et al., 2010; Behr et al., 
2009, 2016; Homma et al., 2012; Huang et 
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al., 2015; Kamio et al., 2014; Martinez et al., 
2014; Okuda et al., 2016; Raghu et al., 2012; 
Sakamoto et al., 2013, 2015; Tomioka et al., 
2005) and these studies were included in 
present systematic reviews and meta-
analysis. Effect of antioxidant such as N-
acetylcysteine (NAC) has been studied as a 
single agent or in combination, with variable 
results (Bando et al., 2010; Behr et al., 2009, 
2016; Homma et al., 2012; Huang et al., 
2015; Martinez et al., 2014; Okuda et al., 
2016; Raghu et al., 2012; Sakamoto et al., 
2013, 2015; Tomioka et al., 2005) where 
lecithinized superoxide dismutase (PC-SOD) 
have been studied as a single agent (Kamio 
et al., 2014). Previous reports showed that 
there was no significant impact on Δ%DLco 
by treatment with single antioxidant therapy 
(SMD=0.12, 95% CI: -0.06–0.30; P=0.18) 
(Sun et al., 2016), whereas use of a 
combination of antioxidant with other 
therapies resulted in a significant improve-
ment in Δ%DLco (SMD = 0.15, 95% CI: 
0.00 to 0.29; P = 0.05). Thus, treatment with 
a combination of antioxidants may be bene-
ficial for amelioration the alteration in DLco 
rather than treating with single antioxidant.  
On the basis of results of the present me-
ta-analysis, it can be supported that antioxi-
dants play a supportive role in the improving 
QoL of IPF patients reflected by providing 
the benefits in terms of VC and DLco. The 
result of the present meta-analysis is in con-
trast with the findings of some previous clin-
ical trials which advocate antioxidants un-
likely to be beneficial in IPF (Bando et al., 
2010; Behr et al., 2016; Martinez et al., 
2014). Alteration in VC and DLco are the 
hallmarks of IPF and their amelioration by 
antioxidant proves its therapeutic potential 
for IPF treatment. Findings of the present 
meta-analysis showed that antioxidant exerts 
a beneficial effect in terms of VC and DLco 
thus support its potential of ameliorating 
IPF. 
Antioxidants are widely used for the 
treatment of an array of diseases with or 
without the advice of their physician. How-
ever, they may associate with serious ad-
verse effects. The results of our meta-
analysis showed that antioxidants failed to 
provide discernible benefits exhibited by 
reduced adverse events. As antioxidant 
treatment is associated with an array of 
adverse events (such as a headache, nausea, 
constipation, allergies, and diarrhea), thus 
number of patients were withdrawn from 
studies, and we generated the results by ex-
trapolating these dropouts. Thus, it was not 
surprising that adverse events were more in 
the antioxidant than the placebo group. Fur-
thermore, these adverse events were minimal 
and manageable with additional supportive 
treatments. Although antioxidants were 
associated with mild adverse events but a 
subsequent meta-analysis of eleven studies 
showed that it did not associate with a signif-
icant mortality (OR = 0.96, 95% CI: 0.44 to 
2.11; P = 0.92). 
Using statistical methods, we analyzed 
the results of various studies to overcome the 
limits of earlier studies where single antioxi-
dant was used for the treatment of IPF. Re-
sults of present study evidence that use of 
antioxidants monotherapy showed promising 
efficacy in IPF patients. However, results did 
not show any beneficial effect on changes in 
predicted carbon monoxide diffusing capaci-
ty. Interestingly, when we focused on the 
combined antioxidant trials, a strong associa-
tion of antioxidants with predicted carbon 
monoxide diffusing capacity in patients with 
IPF was observed.  
This meta-analysis has potential limita-
tions which include the use of significant 
clinical heterogeneity and low statistical 
power. We applied random-effects model to 
address residual heterogeneity in subsequent 
subgroup analysis. Furthermore, the studies 
were grossly disparate in their use of antiox-
idant agents, high dropout rates, duration of 
follow-ups, and dosing regimens. Also, some 
studies included in this meta-analysis lacked 
necessary data, thus hindering the assess-
ment of some meaningful end points. In the 
light of these considerations, additional high-
quality randomized controlled trials (RCTs) 
are needed to add weight to the analysis and 
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formulate robust evidence-based clinical 
recommendations. 
In conclusion, results of the present me-
ta-analysis indicate that oxidative stress 
plays a vital role in the pathophysiology of 
IPF, and combined antioxidant therapy may 
provide comparatively higher clinical im-
provements (e.g. VC, and DLco improve-
ments) compared to monotherapy. However, 
further research in subgroups of patients with 
IPF who obtain optimal benefit from com-
bined antioxidant therapy needs investiga-
tional credence.  
 
IMPLICATIONS FOR RESEARCH  
The nature of outline and presentation of 
the studies was mostly poor. Methodology as 
well as the approach was frequently and not 
entirely depicted. The studies were, for the 
most part, underpowered to demonstrate any 
advantage that might be available over other 
treatments. In future, it will be imperative 
that the entry characteristics of the patient 
are well characterized, and if possible com-
parable between trials. There should be well-
defined inclusion, exclusion criteria and pri-
mary outcome measures used. As well as, a 
more detailed description of adverse events 
is needed. 
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